Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?

Gajic-Veljanoski O, Bayoumi AM, Tomlinson G, Khan K, Cheung AM.

Osteoporos Int. 2012 Nov;23(11):2681-92. doi: 10.1007/s00198-012-1939-4. Epub 2012 Mar 8.

PMID:
22398856
2.
3.

Cost-effectiveness analysis of hip fracture prevention with vitamin D supplementation: a Markov micro-simulation model applied to the French population over 65 years old without previous hip fracture.

Zarca K, Durand-Zaleski I, Roux C, Souberbielle JC, Schott AM, Thomas T, Fardellone P, Benhamou CL.

Osteoporos Int. 2014 Jun;25(6):1797-806. doi: 10.1007/s00198-014-2698-1. Epub 2014 Apr 2.

PMID:
24691648
4.

Vitamin K to prevent fractures in older women: systematic review and economic evaluation.

Stevenson M, Lloyd-Jones M, Papaioannou D.

Health Technol Assess. 2009 Sep;13(45):iii-xi, 1-134. doi: 10.3310/hta13450. Review.

5.

Cost-effectiveness of a fracture liaison service--a real-world evaluation after 6 years of service provision.

Yong JH, Masucci L, Hoch JS, Sujic R, Beaton D.

Osteoporos Int. 2016 Jan;27(1):231-40. doi: 10.1007/s00198-015-3280-1. Epub 2015 Aug 15.

PMID:
26275439
6.

Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model.

Si L, Winzenberg TM, Jiang Q, Palmer AJ.

Osteoporos Int. 2015 May;26(5):1477-89. doi: 10.1007/s00198-014-2999-4. Epub 2015 Jan 8.

PMID:
25567776
7.

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA.

Osteoporos Int. 2010 Feb;21(2):339-49. doi: 10.1007/s00198-009-0971-5. Epub 2009 Jun 10.

PMID:
19513577
8.

Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.

Appl Health Econ Health Policy. 2013 Oct;11(5):485-97. doi: 10.1007/s40258-013-0047-8.

PMID:
23868102
9.

Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.

Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA.

Osteoporos Int. 2014 Jan;25(1):325-37. doi: 10.1007/s00198-013-2521-4. Epub 2013 Oct 10.

PMID:
24114398
10.

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

Hiligsmann M, Reginster JY.

Bone. 2010 Jul;47(1):34-40. doi: 10.1016/j.bone.2010.03.009. Epub 2010 Mar 18.

PMID:
20303422
11.

Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

Borgström F, Ström O, Kleman M, McCloskey E, Johansson H, Odén A, Kanis JA.

Osteoporos Int. 2011 Mar;22(3):955-65. doi: 10.1007/s00198-010-1291-5. Epub 2010 Jun 8.

PMID:
20532482
12.

Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland.

Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R.

Osteoporos Int. 2012 Nov;23(11):2579-89. doi: 10.1007/s00198-011-1869-6. Epub 2012 Jan 6.

PMID:
22222755
13.

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden.

Willis MS.

Int J Technol Assess Health Care. 2002 Fall;18(4):791-807.

PMID:
12602080
14.

Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry.

Ito K, Leslie WD.

Osteoporos Int. 2015 Aug;26(8):2111-9. doi: 10.1007/s00198-015-3107-0. Epub 2015 Mar 26.

PMID:
25807913
15.

Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures.

Ethgen O, Hiligsmann M, Burlet N, Reginster JY.

Osteoporos Int. 2016 Jan;27(1):301-8. doi: 10.1007/s00198-015-3319-3. Epub 2015 Sep 22.

16.

Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture.

Majumdar SR, Lier DA, Rowe BH, Russell AS, McAlister FA, Maksymowych WP, Hanley DA, Morrish DW, Johnson JA.

Osteoporos Int. 2011 Jun;22(6):1799-808. doi: 10.1007/s00198-010-1412-1. Epub 2010 Sep 29.

PMID:
20878389
17.

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Ström O, Jönsson B, Kanis JA.

Osteoporos Int. 2013 Apr;24(4):1491-502. doi: 10.1007/s00198-012-2115-6. Epub 2012 Dec 7.

PMID:
23224141
18.

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.

Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH.

Pharmacoeconomics. 2008;26(4):311-28.

PMID:
18370566
19.

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.

Nayak S, Roberts MS, Greenspan SL.

Ann Intern Med. 2011 Dec 6;155(11):751-61. doi: 10.7326/0003-4819-155-11-201112060-00007.

20.

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA.

Osteoporos Int. 2010 Mar;21(3):495-505. doi: 10.1007/s00198-009-0989-8. Epub 2009 Jun 30.

PMID:
19565175

Supplemental Content

Support Center